SYS-CON MEDIA Authors: Michael Bushong, Eric Brown, Gilad Parann-Nissany, Kevin Benedict, PR.com Newswire

News Feed Item

Plandai Biotechnology, Inc. Announces Favorable Results for Human Clinical Trial

Phytofare(TM) Catechin Complex Delivers "Statistically Significant" Anti-Aging Benefits

SEATTLE, WA -- (Marketwired) -- 03/20/14 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced favorable results from a recent human clinical trial involving a topical preparation of its Phytofare™ Catechin Complex. The study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity.

The results, which were released to the company on March 17, stated that Phytofare yielded "statistically significant" results when compared to a baseline product. The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare™, to skin patches which were tested at 14, 28, and 42 days.

The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare™ improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%. Both of these measures were deemed "statistically significant" by the researcher.

In testing skin hydration, a Corneometer® was used to measure the change in the dielectric constant due to skin surface hydration. The study showed the Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product. The study pointed out that skin hydration improved significantly at 28 days and then maintained that level throughout the study.

The elastic properties reflect the skin's ability to return to its initial position after deformation and can be effected by chronological- and photo aging of the skin. Skin elasticity was evaluated by means of a Cutometer®. The study showed an average improvement in skin elasticity of 1% at 42 days, though there was significant inter subject variation which rendered the results inconclusive with a recommendation for a larger sample size and longer duration for a future study.

Plandaí Vice President Jamen Shively commented, "This study validates the last decade of research and illustrate the benefits of enhanced bioavailability. We envision our Phytofare™ topical formulation serving as the backbone for a host of potential cosmetic products and look forward to sharing the results with our distribution partners as we near release of Phytofare to the market."

The company has placed an abstract of the study on its website: www.plandaibiotech.com.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaíbiotech.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.